Deals this week: Ritter Pharmaceuticals, Sienna Biopharmaceuticals, Exscientia

Ritter Pharmaceuticals has announced a public offering of class A units to raise $10m.

The US-based pharmaceutical company plans to use the funds for general corporate purposes, including research and development (R&D) programmes and working capital.

US-based Sienna Biopharmaceuticals plans to raise $74.75m through an initial public offering (IPO) of common stock shares.

Sienna plans to use the funds from the offering towards the development of SNA-120.

"US-based Sienna Biopharmaceuticals plans to raise $74.75m through an initial public offering (IPO) of common stock shares."

Exscientia has formed a strategic partnership with GlaxoSmithKline (GSK) to carry out drug programmes for the latter.

The artificial intelligence-based drug discovery company will undertake programmes aimed at discovering novel and selective small molecules for various targets identified by GSK.

Australian life science company BARD1 Life Sciences has announced two offerings of 137 million common stock shares and 125 million shares priced at A$0.008 ($0.006) a share, to raise a total of A$2m ($1.6m).

BARD1 plans to use the funds towards R&D programmes and for general corporate purposes.

Free Whitepaper

Revolutionising chromatography and clarification in biopharma production

Biopharma companies are under constant pressure to improve productivity, maintain product purity, and cut costs. Yet this is far from straightforward. Process intensification is desired, but there are barriers to making processes more efficient. Chromatography and clarification play vital parts in biopharma manufacturing, yet there is room for improvement in processes to eliminate inefficiencies and increase yield. Single-stage clarification technologies, such as 3M™ Harvest RC Chromatographic Clarifier, could play a vital role in this journey, by simplifying what would otherwise be a time-consuming and complex clarification train. This document delves into the history of chromatography and clarification, addresses problems, proposes solutions, and offers a glimpse into what the future may look like after a revolution in biopharma production processing. Download to learn more.

By 3M

The information you provide are used by 3M Company and its group companies, in accordance with 3M Global Privacy Policy as shown at 3M.com/privacy, for the purpose of (i) following up with you via email or telephone on any event sponsored / co-organized / participated by 3M, your questions, interests or requests; (ii) making materials available to you; and (iii) inviting you to future events; and (iv) based on your consent, sending you newsletters, advertisements, surveys and information about promotions and offers of 3M Company and its group companies via email. Please use the Intake form to object. EMEA residents: please read 3M privacy notice, opt in language & exact information on 3M data controller relevant to your location here

By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.